NEWS
Study Forecasts Savings for Marker-based Colorectal Cancer Treatment
Using the anti-EGFR therapy cetuximab (Erbitux) to treat patients with metastatic colorectal cancer who have the normal form of the KRAS gene—and not the mutant form—would save more than $600 million annually, according to study results presented January 14 at the Gastrointestinal Cancers Symposium in San Francisco. Read more > >
Removal of Ovaries and Fallopian Tubes Cuts Cancer Risk for BRCA1/2 Carriers
A meta-analysis clarifies the degree of risk reduction with salpingo-oophorectomyDouble Transplantation of One's Own Stem Cells Is Not Warranted for Multiple Myeloma
A meta-analysis shows that tandem autologous hematopoietic stem cell transplant carries risks without a survival benefitRace May Not Be a Survival Factor in Triple-negative Breast Cancer
With similar treatment, African American women have similar survival outcomes as women of other racesMethod Could Reveal Fused Genes in Common Cancers
A new technique can identify an underappreciated class of mutations in cancer
COMMENTARY
Director's Update: Prelude to a New Chapter in the National Cancer Program
One week ago today the country inaugurated Barack Obama as our new president, an occasion accompanied by the excitement associated with such a historic election. There are great expectations that the new president will make significant changes—changes that will touch nearly every aspect of our daily lives, patient care and cancer research included. As a citizen and as NCI director, I share those expectations, the anticipation, and excitement of hope. The hope for an adjustment to our country's compass toward the renewed investment in science, in the creation of new knowledge, and in the education of our talented young people. Read more > >
A Conversation With...Dr. Richard Troiano
An NCI epidemiologist discusses the goals and implications of the 2008 Physical Activity Guidelines for Americans. Read more > >
| Subscribe Now! |
IN DEPTH
Spotlight: Lowly Fruit Fly Reveals Genetic Factors in Cancer and Metastasis
Drosophila melanogaster has long been an indispensable model organism for genetics research, but its use in cancer genetics has been fairly limited, until recently
A Closer Look: Cancer Imaging Looks Beyond Jellyfish Genes
Fluorescent proteins, which have illuminated aspects of biology that were long hidden, could enter the clinic
Featured Clinical Trial: Inhibiting Tumor Angiogenesis in Children
What dosage of the angiogenesis inhibitor cediranib is safe for pediatric and adolescent patients?
Community Update: Clinicians, Cooperative Groups Work through Leucovorin Shortage
A shortage of the chemotherapy drug leucovorin is causing some concern about patient care and the conduct of clinical trials
UPDATES
HHS Update
- Top Department Heads Step Down
Notes
- Gillanders Named an EGRP Branch Chief
- NCI Symposium Addresses Impact of Biospecimens on Cancer Research
- Gillanders Named an EGRP Branch Chief
The NCI Cancer Bulletin is produced by the National Cancer Institute (NCI), which was established in 1937. Through basic, clinical, and population-based biomedical research and training, NCI conducts and supports research that will lead to a future in which we can identify the environmental and genetic causes of cancer, prevent cancer before it starts, identify cancers that do develop at the earliest stage, eliminate cancers through innovative treatment interventions, and biologically control those cancers that we cannot eliminate so they become manageable, chronic diseases.
For more information about cancer, call 1-800-4-CANCER or visit http://www.cancer.gov.
NCI Cancer Bulletin staff can be reached at ncicancerbulletin@mail.nih.gov.
